1. Characterization of T and B cell epitopes in PvCyRPA by studying the naturally acquired immune response in Brazilian Amazon communities
- Author
-
Isabela Ferreira Soares, Barbara de Oliveira Baptista, Ada da Silva Matos, Rodrigo Nunes Rodrigues-da-Silva, Mario Antonio Kujbida Junior, Letusa Albrecht, Cinthia Magalhães Rodolphi, Kézia Katiani Gorza Scopel, Ana Luiza Carneiro Alencar, Rodrigo Medeiros de Souza, Hugo Amorim dos Santos de Souza, Evelyn Kety Pratt Riccio, Jenifer Peixoto de Barros, Paulo Renato Rivas Totino, Cláudio Tadeu Daniel-Ribeiro, Lilian Rose Pratt-Riccio, and Josué da Costa Lima-Junior
- Subjects
Medicine ,Science - Abstract
Abstract Plasmodium vivax, a challenging species to eliminate, causes millions of malaria cases globally annually. Developing an effective vaccine is crucial in the fight against vivax malaria, but considering the limited number of studies focusing on the identification and development of P. vivax-specific vaccine candidates, exploring new antigens is an urgent need. The merozoite protein CyRPA is essential for P. falciparum growth and erythrocyte invasion and corresponds to a promising candidate antigen. In P. vivax, a single study with multiple vaccine candidates indicates PvCyRPA with strong association with protection, outperforming classic malaria vaccine candidates. However, little is known about the specific naturally acquired response in the Americas, as well as the antigen epitope mapping. For this reason, we aimed to investigate the cellular and humoral immune response elicited against PvCyRPA in Brazilian endemic areas to identify the existence of immunodominant regions and the potential of this protein as a single or even a multi-stage specific malaria vaccine candidate for P. vivax. The results demonstrated that PvCyRPA is naturally immunogenic in Brazilian Amazon individuals previously exposed to malaria, which presented anti-PvCyRPA cytophilic antibodies. Moreover, our data show that the protein also possesses important immunogenic regions with an overlap of B and T cell epitopes. These data reinforce the possibility of including PvCyRPA in vaccine formulations for P. vivax.
- Published
- 2024
- Full Text
- View/download PDF